HIV

The following document examines various states' minor consent and confidentiality laws. A minor is a person who does not have the legal rights and responsibilities of an adult. Minors’ ability to access PrEP independently, i.e., without parental or guardian consent, varies throughout the United States. States allowing minors to autonomously consent to PrEP does not mean that access to the health care service will remain confidential.

People with HIV living in the 12 states that have not adopted the Medicaid expansion face limited access to health coverage. In 2018, across sampled states, 20% of people with HIV living in non-expansion states were uninsured compared to 6% in expansion states, and those in expansion states were more likely to have Medicaid coverage (46% v 30%).

This guidance document was designed to assist a variety of harm reduction programs — ranging from small-scale grassroots organizations to larger harm reduction programs — with navigating the funding landscape and fulfilling the requirements laid out in grant proposals and their application process.

This resource provides sample materials, considerations, and resources to assist health departments with developing and implementing a table-top activity in their respective communities.

To commemorate the 33rd World AIDS Day, on December 1, 2021, Treatment Action Group in collaboration with the HIV Vaccine Trials Network, Southern AIDS Coalition, and Black AIDS Institute held this webinar to reflect on the past and celebrate the many successes and innovations in biomedical research that help to shape the prevention landscape for community members, people living with HIV, advocates, and researchers. 

Use this interactive map to help you determine if your state has a Section 1115 Medicaid waiver and the impact on Medicaid beneficiaries living with or at risk for HIV and hepatitis. Please see NASTAD’s related Medicaid resources: Medicaid 1115 Waivers: Considerations for HIV and Hepatitis Programs and Medicaid 1115 Waivers: Exemptions for People Living with HIV and Hepatitis. Additional information about approved and pending waivers can be found on the Centers for Medicare & Medicaid Services website.

On Thursday, December 9, HIV.gov hosted “The Updated National HIV/AIDS Strategy: What’s New and What’s Next? A Webinar on How to Use the Strategy ”, led by Harold Phillips, Director, The White House Office of National AIDS Policy (ONAP). Topics included how the Strategy can be used in communities, as well as how community-based organizations and federal officials plan to use the Strategy within their own communities and departments.

This National HIV/AIDS Strategy (the Strategy), the nation’s third national HIV strategy, updates the HIV National Strategic Plan (2021). The Strategy sets forth bold targets for ending the HIV epidemic in the United States by 2030, including a 75% reduction in new HIV infections by 2025 and a 90% reduction by 2030

Recent news about HIV biomedical prevention research has been a mixed bag: very encouraging results from long-acting pre-exposure prophylaxis (PrEP) trials, but a disappointing lack of significant protection achieved with experimental HIV vaccines. Furthermore, the entire research effort has had to wrestle with the impact of the COVID-19 pandemic.

Este resumen ofrece un panorama general de la profilaxis de post-exposición (PEP) al virus VIH (virus de inmunodeficiencia humana)